



CPT® Editorial Summary of Panel Actions September 2022 Electronic Meeting

CPT® Editorial Summary of Panel Actions September 2022

Please be aware that this action is a reflection of the discussion at the most recent telephonic Panel meeting.

The SARS-CoV-2 Vaccine product CPT code and immunization CPT codes can be found on the [AMA Website](#).

Addition of 8 Category I codes (0124A, 0134A, 0144A, 0154A, 91312, 91313, 91314, 91315) accepted by the CPT Editorial Panel. Codes 0124A, 0134A, 0144A, 0154A, 91312, 91313, 91314, 91315, and all related references will be published in CPT 2024. Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.

Update code range to 91300-91315 by replacing 91311 with 91315 throughout the code set.

Update Appendix Q table to revise vaccine name and NDC for code 91301.

Name	Code #	Description of Editorial Panel Action	Effective Date
Immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only	#●0124A #●0134A #●0144A, #●0154A	Accepted addition of codes 0124A, 0134A, 0144A, 0154A for immunization administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine only. Each administration code is specific to each individual vaccine product (eg, 91312); accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include codes 0124A ,0134A, 0144A, 0154A; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines	#↗●91312 #↗●91313 #↗●91314 #↗●91315	Accepted addition of codes 91312, 91313, 91314, 91315 to report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines; accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV2 vaccine CPT reporting, to include codes 91312, 91313, 91314, 91315; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration